Filgrastim and Alemtuzumab (Campath-1h) for Refractory Chronic Lymphocytic Leukemia

Leukemia - United Kingdom
doi 10.1038/sj.leu.2403782
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Remission of Chronic Inflammatory Demyelinating Polyneuropathy After Alemtuzumab (Campath 1H)

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2006English

First-Line Treatment of Chronic Lymphocytic Leukemia: Role of Alemtuzumab

OncoTargets and Therapy
OncologyPharmacology
2010English

Refractory Chronic Lymphocytic Leukemia – New Therapeutic Strategies

Oncotarget
Oncology
2010English

The Use of Low-Dose Alemtuzumab in Pretreated B-Cell Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Oncologist
Cancer ResearchMedicineOncology
2008English

R-Dhap Is Effective in Fludarabine-Refractory Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Chronic Lymphocytic Leukemia

Current Opinion in Hematology
Hematology
1998English

Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy